Genscript Biotech Co. (OTCMKTS:GNNSF – Get Free Report)’s stock price rose 46.5% on Friday . The company traded as high as C$2.93 and last traded at C$2.93. 9,078 shares traded hands during mid-day trading, an increase of 61% from the average session volume of 5,631 shares. The stock had previously closed at C$2.00.
Genscript Biotech Stock Performance
The firm has a 50 day moving average price of C$1.71 and a 200-day moving average price of C$1.64.
About Genscript Biotech
GenScript Biotech Corporation is a global contract research, development and manufacturing organization (CDMO) specializing in synthetic biology and biopharmaceutical services. Founded in 2002, the company provides end-to-end solutions that span gene and peptide synthesis, recombinant protein expression, custom antibody discovery and cell line development. GenScript’s integrated platforms support early-stage discovery through to process development, enabling academic institutions, biotech innovators and pharmaceutical companies to accelerate research timelines.
The company’s core offerings include molecular biology services such as DNA construction, gene editing using CRISPR/Cas9 technology and high-throughput peptide libraries.
Further Reading
- Five stocks we like better than Genscript Biotech
- 3 Stocks Whose Charts May Be Signaling the Next Big Move
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
- Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
Receive News & Ratings for Genscript Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genscript Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
